1-20 of 249 Search Results for

pbmc-peripheral-blood-mononuclear-cell

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Images
Changes in resistin, cytokines, and glucose in acute endotoxemia in <italic
Published: 21 February 2011
FIG. 2. Changes in resistin, cytokines, and glucose in acute endotoxemia in BAC-Retn mice. Acute LPS (0.2 mg/kg) or normal saline (0.9%) intraperitoneal administration to Rko (□) and BAC-Retn (■) mice (n = 5–7 per group). A and B: Human resistin was induced in response to LPS in vivo in BAC-Retn mice. C and D: Serum TNF-α and IL1β levels increased similarly in Rko and BAC-Retn mice. E: LPS-induced hypoglycemia is less severe in BAC-Retn than in Rko mice at 6 h after LPS injection. F: Serum insulin levels in 6 h after LPS injection. PBMC, peripheral blood mononuclear cells. Data are presented with the SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. saline; #P < 0.05 vs. Rko. FIG. 2. Changes in resistin, cytokines, and glucose in acute endotoxemia in BAC-Retn mice. Acute LPS (0.2 mg/kg) or normal saline (0.9%) intraperitoneal administration to Rko (□) and BAC-Retn (■) mice (n = 5–7 per group). A and B: Human resistin was induced in response to LPS in vivo in BAC-Retn mice. C and D: Serum TNF-α and IL1β levels increased similarly in Rko and BAC-Retn mice. E: LPS-induced hypoglycemia is less severe in BAC-Retn than in Rko mice at 6 h after LPS injection. F: Serum insulin levels in 6 h after LPS injection. PBMC, peripheral blood mononuclear cells. Data are presented with the SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. saline; #P < 0.05 vs. Rko. More
Images
Generation and characterization of BAC-transgenic (<em>BAC-Retn</em>...
Published: 21 February 2011
FIG. 1. Generation and characterization of BAC-transgenic (BAC-Retn) mice. A: A BAC that contains the human resistin gene plus all the DNA elements up to 21,300 bp upstream and 4,248 bp downstream relative to the human resistin start site is used to generate the mice. The fusion construct was excised using NotI/BglII and injected into the pronucleus of fertilized C57BL/6 J mouse oocytes. B: Induction of human resistin gene by LPS (100 ng/mL) in transfected RAW.264 macrophages. C: LPS (100 ng/mL) induced secretion of resistin in transfected RAW.264 macrophages. D: Expression profile of human resistin in different tissues in BAC-Retn mice. E: LPS induced human resistin in vitro in peritoneal macrophages from BAC-Retn mice (n = 5 per group). Data are presented with the SEM. BAT, brown adipose tissue; BM, bone marrow; L. int, large intestine; PBMC, peripheral blood mononuclear cells; S. int, small intestine. *P < 0.05, **P < 0.01 vs. saline. FIG. 1. Generation and characterization of BAC-transgenic (BAC-Retn) mice. A: A BAC that contains the human resistin gene plus all the DNA elements up to 21,300 bp upstream and 4,248 bp downstream relative to the human resistin start site is used to generate the mice. The fusion construct was excised using NotI/BglII and injected into the pronucleus of fertilized C57BL/6 J mouse oocytes. B: Induction of human resistin gene by LPS (100 ng/mL) in transfected RAW.264 macrophages. C: LPS (100 ng/mL) induced secretion of resistin in transfected RAW.264 macrophages. D: Expression profile of human resistin in different tissues in BAC-Retn mice. E: LPS induced human resistin in vitro in peritoneal macrophages from BAC-Retn mice (n = 5 per group). Data are presented with the SEM. BAT, brown adipose tissue; BM, bone marrow; L. int, large intestine; PBMC, peripheral blood mononuclear cells; S. int, small intestine. *P < 0.05, **P < 0.01 vs. saline. More
Images
Schematic representation of the balance of clinical trial activity in type ...
Published: 01 September 2010
FIG. 2. Schematic representation of the balance of clinical trial activity in type 1 diabetes. Data are modeled onto a graphical representation of diabetes progression (adapted from reference [ 38 ]; reprinted with permission from Atkinson). Data are separated in two dimensions. First, according t... More
Images
Analysis of <span class="search-highlight">Peripheral</span> <span class="search-highlight">Blood</span> <span class="search-highlight">Mononuclear</span> <span class="search-highlight">Cells</span> (<span class="search-highlight">PBMC</span>) was performed at vari...
Published: 01 September 2010
FIG. 1. Analysis of Peripheral Blood Mononuclear Cells (PBMC) was performed at various time points after transplantation in diabetic NOD mice. CD4+ and CD8+ T-cell depletion is detected on day 7 after mATG treatment (untreated vs. all treatment, P < 0.05) (A–C). Addition of CTLA4-Ig slowed reconstitution after mATG depletion on day 14 (CD3+, CD4+, and CD8+ cells: prolonged mATG+CTLA4-Ig vs. prolonged mATG, P < 0.05). On day 28, peripheral T-cell percentage in animals treated with prolonged mATG+CTLA4-Ig was similar to that of animals treated with induction mATG+CTLA4-Ig (P = NS). On day 7, FoxP3+CD25+CD4+ (Tregs) was increased by both induction and prolonged mATG treatment (P < 0.05 vs. day 7 untreated), and on day 14 by prolonged mATG treatment (P < 0.05 vs. day 7 untreated) (D). Addition of CTLA4-Ig abrogated this increase (day 7: induction mATG+CTLA4-Ig vs. induction mATG, P = 0.04; day 7 and day 14 prolonged mATG+CTLA4-Ig vs. prolonged mATG, P = 0.002 and P = 0.008, respectively) (D). Peripheral Treg frequency at day 28 was increased with prolonged mATG + CTLA4-Ig treatment compared with induction mATG+CTLA4-Ig treatment (P < 0.05) (D). On day 14, a relative increase in CD44highCD62lowCD4+ cells (Teffs) was evident with prolonged mATG treatment (P < 0.05 vs. day 7 untreated); this increase was prevented by the addition of CTLA4-Ig (prolonged mATG+CTLA4-Ig vs. prolonged mATG, P = 0.0001) (E). On day 28, Teffs were increased in the prolonged mATG+CTLA4-Ig group compared with the induction group (P < 0.05) (E). *P < 0.05. FIG. 1. Analysis of Peripheral Blood Mononuclear Cells (PBMC) was performed at various time points after transplantation in diabetic NOD mice. CD4+ and CD8+ T-cell depletion is detected on day 7 after mATG treatment (untreated vs. all treatment, P < 0.05) (A–C). Addition of CTLA4-Ig slowed reconstitution after mATG depletion on day 14 (CD3+, CD4+, and CD8+ cells: prolonged mATG+CTLA4-Ig vs. prolonged mATG, P < 0.05). On day 28, peripheral T-cell percentage in animals treated with prolonged mATG+CTLA4-Ig was similar to that of animals treated with induction mATG+CTLA4-Ig (P = NS). On day 7, FoxP3+CD25+CD4+ (Tregs) was increased by both induction and prolonged mATG treatment (P < 0.05 vs. day 7 untreated), and on day 14 by prolonged mATG treatment (P < 0.05 vs. day 7 untreated) (D). Addition of CTLA4-Ig abrogated this increase (day 7: induction mATG+CTLA4-Ig vs. induction mATG, P = 0.04; day 7 and day 14 prolonged mATG+CTLA4-Ig vs. prolonged mATG, P = 0.002 and P = 0.008, respectively) (D). Peripheral Treg frequency at day 28 was increased with prolonged mATG + CTLA4-Ig treatment compared with induction mATG+CTLA4-Ig treatment (P < 0.05) (D). On day 14, a relative increase in CD44highCD62lowCD4+ cells (Teffs) was evident with prolonged mATG treatment (P < 0.05 vs. day 7 untreated); this increase was prevented by the addition of CTLA4-Ig (prolonged mATG+CTLA4-Ig vs. prolonged mATG, P = 0.0001) (E). On day 28, Teffs were increased in the prolonged mATG+CTLA4-Ig group compared with the induction group (P < 0.05) (E). *P < 0.05. More
Journal Articles
Journal: Diabetes
Diabetes 1991;40(9):1128–1133
Published: 01 September 1991
... and the evaluation of intervention therapy to avert autoimmune-mediated β-cell destruction. In subjects with preclinical or clinical IDDM, we measured the reactivity of peripheral blood mononuclear cells (PBMCs) incubated over 6 days with either adult human islets or fetal pig proislets, or other fetal pig tissues...
Meeting Abstracts
Journal: Diabetes
Diabetes 1999;48(5):983–988
Published: 01 May 1999
...B M Brooks-Worrell; R Juneja; A Minokadeh; C J Greenbaum; J P Palmer Type 1 diabetes is a cell-mediated autoimmune disease characterized by autoantibody and peripheral blood mononuclear cell (PBMC) reactivity to islet cell proteins. Type 2 diabetes is not an autoimmune disease but rather results...
Meeting Abstracts
Journal: Diabetes
Diabetes 1998;47(4):566–569
Published: 01 April 1998
... autoimmune destruction of the insulin-producing pan- must be studied through cells obtained from peripheral creatic -cells, we analyzed humoral and cellular blood. Peripheral blood mononuclear cells (PBMCs) from immune reactivity to this autoantigen to further define patients with IDDM proliferate in vitro...
Journal Articles
Journal: Diabetes
Diabetes 2002;51(8):2474–2480
Published: 01 August 2002
... 2000 were included in this prospective study. Blood samples were drawn at admission before starting insulin treatment for the isolation of peripheral blood mononuclear cell (PBMCs). All blood samples were transported to our laboratory within 2 h. PBMCs were isolated by Ficoll-Paque density gradient...
Journal Articles
Journal: Diabetes
Diabetes 2003;52(11):2647–2651
Published: 01 November 2003
... polypeptide [IAPP] precursor protein [preproIAPP] 5-13: KLQVFLIVL). Peripheral blood mononuclear cells (PBMCs) were isolated from 18 HLA-A*0201 patients with type 1 diabetes (9 with recent-onset [<180 days; range, 1–120 days] and 9 with long-standing diabetes [>180 days; range, 183–3,273 days]) and 9...
Journal Articles
Journal: Diabetes
Diabetes 1996;45(6):795–800
Published: 01 June 1996
...Ivana Durinovic-Bellò; Michael Hummel; Anette-G Ziegler In IDDM, T-cells are postulated to mediate the destruction of pancreatic β-cells. We analyzed peripheral blood mononuclear cell (PBMC) responses to human insulin, glutamate decarboxylase GAD65, tyrosine phosphatase ICA512, glucagon...
Journal Articles
Journal: Diabetes
Diabetes 2006;55(5):1450–1455
Published: 01 May 2006
...; OREA, OREB, and OREC) in the gene. The aim was to investigate the contribution of NFAT5 to the pathogenesis of diabetic nephropathy. Peripheral blood mononuclear cells (PBMCs) were isolated from the following subjects: 44 Caucasoid patients with type 1 diabetes, of whom 26 had nephropathy and 18 had...
Journal Articles
Journal: Diabetes
Diabetes 2003;52(3):621–633
Published: 01 March 2003
... volunteers who were studied as the control group. Peripheral blood mononuclear cells (PBMCs) were isolated before and at the end of a 2-h clamp. In group C, PBMCs were isolated before and after 2 h without performing a clamp. The euglycemic clamp as well as “no clamp” had no effects on all parameters studied...
Journal Articles
Journal: Diabetes
Diabetes 2006;55(12):3446–3454
Published: 01 December 2006
... regulatory T-cells should exist. We had a chance to study peripheral blood mononuclear cells (PBMCs) from children with type 1 diabetes both before and after starting insulin treatment, and thus we could analyze the effects of insulin treatment on regulatory T-cells in children with type 1 diabetes. PBMCs...
Meeting Abstracts
Journal: Diabetes
Diabetes 1999;48(2):299–303
Published: 01 February 1999
.... Therefore, we analyzed cellular immune reactivities against these molecules in people with or at varying risks for the disease to clarify their role in the pathogenesis of IDDM. In vitro peripheral blood mononuclear cell (PBMC) responses against these antigens, a control antigen (tetanus toxoid...
Journal Articles
Journal: Diabetes
Diabetes 2006;55(4):996–1003
Published: 01 April 2006
...-cell immune response to CVB4 in children with type 1 diabetes and healthy children with and without HLA risk-associated haplotypes (HLA-DR3-DQ2 or HLA-DR4-DQ8) for type 1 diabetes. Peripheral blood mononuclear cells (PBMCs) were isolated and cultured with CVB4 and analyzed for cytokine and chemokine...
Images
Immune <span class="search-highlight">cell</span> subsets in YES mice. Splenocytes (<em>A</em>), iLN <span class="search-highlight">cell</span>...
Published: 02 July 2018
Figure 2 Immune cell subsets in YES mice. Splenocytes (A), iLN cells (B), peripheral blood mononuclear cells (PBMCs) (C), and thymocytes (D) were stained using the following antibodies: anti-CD19 (B cells), anti-CD11c (DCs), anti-CD11b (macrophages), anti-NKp46 (natural killer [NK] cells), and anti-CD3ε (T cells; CD3low, CD3high). T-cells subsets were further stained with anti-CD4 and anti-CD8α monoclonal antibodies (gray). A population of immature cells (ICs) was detected in YES mice (gold and Supplementary Fig. 3 ). Figure 2. Immune cell subsets in YES mice. Splenocytes (A), iLN cells (B), peripheral blood mononuclear cells (PBMCs) (C), and thymocytes (D) were stained using the following antibodies: anti-CD19 (B cells), anti-CD11c (DCs), anti-CD11b (macrophages), anti-NKp46 (natural killer [NK] cells), and anti-CD3ε (T cells; CD3low, CD3high). T-cells subsets were further stained with anti-CD4 and anti-CD8α monoclonal antibodies (gray). A population of immature cells (ICs) was detected in YES mice (gold and Supplementary Fig. 3). More
Journal Articles
Journal: Diabetes
Diabetes 2002;51(7):2294–2300
Published: 01 July 2002
... polymorphisms (41 Bangladeshi subjects) and analyzed insulin secretory capacity (143 Bangladeshi subjects), allowing for other known determinants. Peripheral blood mononuclear cells (PBMCs) from subjects who had been genotyped for BsmI, ApaI, TaqI, and FokI VDR restriction...
Journal Articles
Journal: Diabetes
Diabetes 1997;46(4):583–588
Published: 01 April 1997
... Institute, Mannerheimintie 166, 00300 Helsinki, Finland. outi.vaarala@ktl.fi . 1 ACT-1, α4β7-integrin; APD-I, autoimmune polyendocrine disease type 1; cpm, counts per minute; ICA, islet cell antibody; MAdCAM-1, mucosal vascular addressin; PBMC, peripheral blood mononuclear cell...
Journal Articles
Journal: Diabetes
Diabetes 2008;57(3):525–526
Published: 01 March 2008
...-trimester human fetal pancreata were transplanted under the renal capsule of NOD/Scid mice that, 1 week later, received 5 × 107 human peripheral blood mononuclear cells (PBMCs). Histological examination of the second-trimester grafts revealed an extensive cellular infiltration, and the engrafted...
Meeting Abstracts
Journal: Diabetes
Diabetes 2022;71(Supplement_1):437-P
Published: 01 June 2022
...TOMASZ J. BLOCK; KARLY SOURRIS; WAHEED KHAN; PHILLIP KANTHARIDIS; JAY C. JHA; MARK E. COOPER; JAMES SHAW; KARIN JANDELEIT-DAHM Background: Human NADPH oxidase 5 (NOX5) is expressed and functionally active in peripheral blood mononuclear cells (PBMCs) . In those with diabetes, there is increased...